Marcus Smith Noel

Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma

Marcus Smith Noel, Eileen M. O’Reilly, Brian M. Wolpin et al. · Investigational New Drugs · 2019 · 174 citations · Full text

Adjuvant <i>nab</i> -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial

Margaret A. Tempero, Uwe Pelzer, Eileen M. O’Reilly et al. · Journal of Clinical Oncology · 2022 · 120 citations · Full text

Comparison of outcomes between SBRT, yttrium-90 radioembolization, transarterial chemoembolization, and radiofrequency ablation as bridge to transplant for hepatocellular carcinoma

Mostafa Mohamed, Alan W. Katz, Mohamedtaki Abdulaziz Tejani et al. · Advances in Radiation Oncology · 2015 · 93 citations · Full text

Overall survival in a trial of orally administered CCR2 inhibitor CCX872 in locally advanced/metastatic pancreatic cancer: Correlation with blood monocyte counts.

David C. Linehan, Marcus Smith Noel, Aram F. Hezel et al. · Journal of Clinical Oncology · 2018 · 90 citations

Immunology, Pathology, Immunotherapeutics +19

Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)

Douglas B. Johnson, Fengmin Zhao, Marcus Smith Noel et al. · Clinical Cancer Research · 2020 · 88 citations · Full text